Core Viewpoint - OmniAb reported progress in expanding its partner base and advancing partner programs, despite lower revenue and increased net loss for 2025 [5][6]. Financial Performance - Full-year 2025 revenue decreased to $18.7 million from $26.4 million in 2024, primarily due to declines in license and milestone revenue [17]. - Fourth-quarter 2025 revenue was $8.4 million, down from $10.8 million in the same period of 2024 [15]. - The net loss for 2025 was $64.8 million, or $0.57 per share, compared to a net loss of $62.0 million, or $0.61 per share, in 2024 [17]. - Year-end cash balance was $54 million, with 2026 guidance projecting revenue of $25–30 million and operating expenses of $80–85 million [6][23]. Partner Programs and Pipeline - OmniAb ended 2025 with 107 partners and 407 active programs, adding a net of 44 programs during the year [4][8]. - The partner pipeline showed momentum with 25 advancement events in 2025, including 32 active clinical programs [7][9]. - Eight of the ten largest pharmaceutical companies are active partners of OmniAb [3]. Technology Developments - OmniAb launched two new technologies: OmniUltra, a transgenic chicken platform, and the xPloration Partner Access program, which enhances partner labs' capabilities [12][14]. - The OmniUltra platform is designed to access binding pockets not reachable with other antibodies, potentially enabling smaller binding units [12][13]. Future Outlook - Management anticipates a transition from milestone-driven revenue to more royalty-driven revenue over time, emphasizing scalability and positive cash flow trajectory [20]. - The company expects multiple new entries into clinical development for novel OmniAb-derived programs in 2026 [9].

Core Insights - OmniAb, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.08, representing an earnings surprise of -33.33% [1] - The company posted revenues of $8.38 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 5.14% and down from $10.8 million year-over-year [2] - The stock has underperformed the market, losing about 6.5% since the beginning of the year compared to the S&P 500's decline of 0.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $7.43 million, and for the current fiscal year, it is -$0.36 on revenues of $33.64 million [7] - The estimate revisions trend for OmniAb, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which OmniAb belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, electroCore, Inc., is expected to report a quarterly loss of $0.35 per share, with revenues projected to be $9.26 million, reflecting a year-over-year increase of 31.4% [9]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [29][30] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [32] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [31] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [34] Business Line Data and Key Metrics Changes - The company had 107 active partners by year-end 2025, with 407 active programs, reflecting a net increase of 44 programs during the year [6][12] - The number of program additions in 2025 was 84, significantly higher than in previous years, with over 98% of active programs having contracted future economics to the company [12][13] - The company introduced OmniUltra, a new transgenic chicken platform, which is expected to drive growth and attract new partners [7][26] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [11] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's technology [11] Company Strategy and Development Direction - The company is focused on broadening its partner roster and increasing the number of active programs, with a scalable platform that allows for operational efficiency [9][10] - The introduction of new technologies like OmniUltra and xPloration is expected to enhance growth and expand market reach [7][28] - The company aims to transition from milestone-driven revenue to more royalty-driven revenue, with over $3 billion in contracted milestones [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new entries into clinical development [18][61] - The company anticipates a revenue range of $25 million to $30 million for 2026, indicating a recovery from previous years [37] - The effective tax rate is expected to remain close to 0% due to a full valuation allowance against the income tax benefit associated with net losses [31][38] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [36][38] - Operating expenses decreased to $87.6 million in 2025 from $100.9 million in 2024, reflecting cost control measures [33] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [42][44] Question: Revenue growth expectations for xPloration - Management indicated significant growth potential for xPloration, with strong demand from high-tier partners and multiple revenue streams expected [45][47] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [50][53] Question: Timeline for achieving cash flow break-even - Management stated that while a precise date for achieving break-even cannot be provided, the growing portfolio gives confidence in reaching that goal [60][61] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement and increasing partner programs expected [68][70] Question: Proportion of tiered vs. fixed royalty structures - Management indicated that while most deals are flat royalties, there are some instances of tiered royalties, but it is not the majority [85][89]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [24] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [28] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [26] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [30] Business Line Data and Key Metrics Changes - The company had 107 partners running 407 active programs by year-end 2025, reflecting growth in both partner count and program activity [4][7] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with total contracted milestone payments exceeding $3 billion [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [8] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's partner relationships [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform for ultra-long CDRH3s, which is expected to drive growth and attract new partners [5][20] - The xPloration platform, launched in mid-2025, is positioned for significant growth and aims to enhance partner engagement through high-throughput screening capabilities [6][22] - The company is focused on transitioning revenue from milestone-driven to more royalty-driven streams, with an average royalty rate of 3.4% across its portfolio [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new clinical program entries in 2026 [19][55] - The company anticipates achieving cash flow positivity as it continues to control operating costs while expanding its partner and program portfolio [32] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [30] - The company implemented workforce reductions of 22 employees in 2025, contributing to lower operating expenses [29] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Revenue expectations from xPloration - Management indicated that xPloration is expected to contribute significantly to revenue in 2026, with strong interest from high-tier partners [38][40] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [43][47] Question: Deployment of xPloration systems - Two xPloration instruments were deployed by the end of 2025, with expectations for growth in 2026 [52] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement from partners and an increase in partner programs [62][64] Question: Milestones for OmniUltra in 2026 - The focus for 2026 will be on adding partners and programs leveraging OmniUltra technology [74] Question: Royalty structures for active programs - The majority of active programs have flat royalties, with some having tiered structures [78][81]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [22] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [25][26] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [25] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [27] Business Line Data and Key Metrics Changes - The company had 107 active partners and 407 active programs by year-end 2025, reflecting growth in both partnerships and program activity [4][6] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with over $3 billion in total contracted milestone payments [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [7] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's technology [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform, which is expected to drive growth and attract new partners [5][19] - The xPloration platform is positioned for significant growth, with an expanding pipeline and increasing partner engagement [5][20] - The company aims to transition from milestone-driven revenue to more royalty-driven revenue, with an average royalty rate of 3.4% across its portfolio [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory towards positive cash flow, supported by a scalable business model and controlled operating costs [6][31] - The company anticipates a strong year in 2026 with potential value-creating events and expects revenue to be in the range of $25 million to $30 million [29][30] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments [28] - Operating expenses decreased to $87.6 million in 2025 from $100.9 million in 2024, reflecting cost control measures [26] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Growth expectations for xPloration - Management indicated strong demand for xPloration, with expectations for significant revenue growth from instrument sales and consumables [37][39] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [42][45] Question: Timeline for achieving cash flow break-even - While no precise date was provided, management expressed confidence in reaching break-even due to the growing portfolio of partner programs [53][54] Question: Interest in xPloration from new partners - Management confirmed that xPloration is attracting both existing and new partners, enhancing relationships and creating new opportunities [71][73] Question: Milestones expected from OmniUltra - The initial focus for OmniUltra will be on adding partners and programs, with expectations for continued engagement and development [74]

Financial Performance and Profitability - The company has incurred losses on an as-reported basis for the last several years and may not generate sufficient revenue to achieve and maintain profitability[113]. - For the years ended December 31, 2025 and 2024, the company's revenue was $18.7 million and $26.4 million, respectively, with net losses of $64.8 million and $62.0 million[141]. - The company has incurred net losses for several years and may not generate sufficient revenue to achieve and maintain profitability[141]. - The company’s ability to forecast future revenues may be limited due to the reliance on partners for product development and commercialization[119]. - Revenue is subject to fluctuations based on the timing of license agreements and partners' development milestones, which are outside the company's control[140]. - The company may need to raise additional capital to fund operations and achieve goals, with potential risks associated with equity or debt financing[134]. Market and Competitive Landscape - The commercial success of the company depends on the quality of its antibody discovery platform and technological capabilities, which must be accepted by new and existing partners[125]. - The life sciences and biotech platform technology market is highly competitive, with significant competition in therapeutic antibody discovery[152]. - The company’s platform must demonstrate advantages over legacy technologies to maintain market acceptance and attract new partnerships[127]. - The company faces challenges in marketing its solutions due to its pricing model, which is structured to capture downstream revenues[156]. Regulatory and Compliance Risks - The biopharmaceutical development process is inherently uncertain, and very few therapeutic candidates may progress through clinical development and receive approval for commercialization[129]. - The timing and scope of regulatory approvals required for commercialization of therapeutic candidates developed using the company’s platform are unpredictable and can vary significantly[116]. - Third-party payor coverage and reimbursement status for newly approved therapeutics is uncertain, impacting revenue generation[162]. - The Affordable Care Act (ACA) and subsequent legislative changes have introduced pricing pressures and potential competition from biosimilars[165][166]. - The Inflation Reduction Act of 2022 requires price negotiations for certain drugs, which may significantly impact the pharmaceutical industry[167]. - Future U.S. healthcare reforms may limit government payments for healthcare products, impacting demand and pricing pressures on biopharmaceutical products[171]. - The company may face increased regulatory scrutiny and costs related to evolving healthcare laws and regulations, which could impact business operations[194][196]. Intellectual Property Risks - The company faces risks related to intellectual property protection, which may limit competitive advantages and increase litigation costs[209]. - Changes in patent law could diminish the value of patents, affecting the ability to protect technology[217]. - The evolving regulatory framework for AI Technologies may create uncertainties in compliance and operational practices[203]. - The biotechnology field faces uncertainty regarding patentability due to recent court decisions, which may affect the ability to obtain and enforce patents related to natural laws or abstract ideas[221]. - The company may not be aware of all third-party intellectual property rights, which could lead to challenges against its patents and applications[223]. - The company may face challenges in acquiring or licensing necessary technologies on reasonable terms, which could hinder future commercialization efforts[228]. Operational and Management Challenges - The company engages in ongoing conversations regarding potential partnerships, but these may not result in successful commercial agreements[132]. - The company anticipates further growth in operations, requiring effective management of complexities associated with research and development[148]. - The company must continue to improve its managerial, operational, and financial systems to manage anticipated growth effectively[149]. - The company is dependent on information technology systems for operations; any failure could harm business and reputation[177]. Security and Data Privacy - Security breaches and data loss could compromise sensitive information, exposing the company to liability and harming its reputation[189]. - Compliance with data privacy laws, such as HIPAA and GDPR, is critical, with potential penalties for violations that could adversely affect financial condition[198][200]. - The company invests significant resources in cybersecurity measures to protect sensitive information, but vulnerabilities remain due to evolving threats[190]. Stock and Market Risks - The market price of the company's common stock is likely to be highly volatile, and significant sales of securities by existing shareholders could cause stock prices to decline[113]. - The company faces potential delisting from Nasdaq if it fails to meet continued listing requirements, which could negatively impact stock price and liquidity[272]. - The trading market for the company's common stock will depend on analyst coverage, and negative reports could lead to declines in stock price[279]. - The company does not currently intend to pay dividends, meaning returns for investors will depend solely on stock price appreciation[280]. Economic and Financial Environment - Economic instability and liquidity risks in financial markets could adversely affect the company's business strategy and stock price[267]. - The closures of financial institutions in 2023 raised liquidity risks, potentially impairing access to capital[208]. - Inflation has not had a material effect on the company's consolidated financial statements, although it may increase labor and R&D costs[379].

Q4 and Full Year 2025 Financial Results & Business Update Nasdaq: OABI March 4, 2026 1 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance for 2026, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our ...

Exhibit 99.1 OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (March 4, 2026) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support ...

Core Insights - Biotech shares experienced significant movements in after-hours trading, with Sarepta Therapeutics leading due to anticipated trial data and other companies benefiting from recent clinical and regulatory updates [1] Company Summaries - Sarepta Therapeutics Inc. (SRPT) saw a surge of 9.65% to $23.17, driven by anticipation for a webcast on January 26, 2026, where three-year topline results from its Phase 3 trial of ELEVIDYS for Duchenne muscular dystrophy will be presented, potentially pivotal for its gene therapy program [2] - Fractyl Health, Inc. (GUTS) increased by 7.66% to $2.25, indicating speculative interest despite no new company news, suggesting momentum-driven trading [3] - Greenwich LifeSciences, Inc. (GLSI) advanced 2.08% to $26.00 following FDA approval of the first commercial lot of GP2 vials for the FLAMINGO-01 trial, marking a significant step in its commercialization efforts with the potential to prepare approximately 200,000 doses [4] - Anebulo Pharmaceuticals, Inc. (ANEB) rose 8.41% to $1.16, attracting buyers despite no new updates, reflecting investor interest [5] - OmniAb, Inc. (OABI) gained 4.59% to $2.05, similar to Anebulo, indicating broader investor interest in the biotech sector without fresh news [6] - Trevi Therapeutics, Inc. (TRVI) added 3.40% to $10.33 after publishing results from its Phase 2b CORAL trial in a peer-reviewed journal, enhancing credibility and investor enthusiasm [7] - AEON Biopharma, Inc. (AEON) edged up 1.80% to $1.13, confirming a meeting with the FDA and securing shareholder approval for financing transactions, simplifying its capital structure ahead of a second PIPE financing closing expected around January 27, 2026 [8]

Core Viewpoint - OmniAb Inc. has launched its latest technology, OmniUltra, which is expected to enhance its product offerings and market position [2]. Group 1: Company Overview - Kurt Gustafson serves as the Chief Financial Officer and Executive VP of Finance at OmniAb [2]. - The company is actively engaging with investors and stakeholders through conference calls to discuss developments and innovations [2]. Group 2: Technology Launch - The launch of OmniUltra is a significant milestone for the company, indicating a focus on advancing its technological capabilities [2]. - Accompanying slides are available in the Investors section of the company's website, providing additional context and details about the launch [2].